CPhI Worldwide-organized by UBM (part of Informa PLC)-announced the award entries for the 2018 CPhI Pharma Awards. The industry’s awards return for a 15th edition, with 17 categories honoring companies and individuals driving the pharma industry forward through innovations, technologies, and strategies.
Categories include innovations across APIs, excipients, and formulations to drug delivery technologies, packaging, patient-centricity, contract services, and business performance focused awards.
This year the Bioprocessing & Manufacturing category-powered by the new bioLIVE event-is expected to see an increase in applications in light of the increased biologics and supply chain audiences now attending CPhI Worldwide. Among 2017’s most hotly contested categories were API Development, along with the fiercely competitive ‘Product Packaging’ and ‘Drug Delivery and Devices’ categories. Another increasingly significant category is the Corporate Social Responsibility award.
Submitting your entry(ies) for the CPhI Pharma Awards is free of charge and the deadline is July 31st 2018-with shortlisted finalists announced August 28th, 2018. The winners will be unveiled during a ceremony at the Eurostars Madrid Tower in Madrid, on October 9th during the evening of the first day of CPhI Worldwide.
To apply please visit https://awards.cphi.com
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.